Download PDF
Pharmacopsychiatry 2005; 38(3): 107-112
DOI: 10.1055/s-2005-864119
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

Pharmacophilia and Pharmacophobia: Determinants of Patients’ Attitudes towards Antipsychotic Medication

I. Sibitz1 , H. Katschnig1 , 2 , R. Goessler2 , A. Unger1 , M. Amering1
  • 1Department of Psychiatry, Medical University of Vienna
  • 2Ludwig Boltzmann Institute of Social Psychiatry, Vienna
Further Information

Publication History

Received: 10.4.2004 Revised: 26.7.2004

Accepted: 2.9.2004

Publication Date:
18 May 2005 (online)

Also available at
    Permissions and Reprints

Objective: To identify factors that influence attitudes towards psychopharmacological treatment in patients suffering from schizophrenia and schizoaffective psychoses. Methods: Ninety-two participants in an outpatient psychoeducational program, classed as ”pharmacophobic” or ”pharmacophilic” according to the Drug Attitude Inventory scale, were compared with regard to sociodemographic variables, clinical characteristics, subjective deficit syndrome, illness concepts, knowledge, locus of control, and quality of life. Results: The 59 pharmacophilic and the 33 pharmacophobic patients did not differ significantly with regard to most sociodemographic variables, symptoms, or classic personality traits such as locus of control, self-concept, and quality of life. The only differences concerned hospitalization history (P < 0.05) and statements on the actual, subjective experience of desired and undesired effects of medication (P < 0.01). Conclusions: The impact of subjective experiences with drug treatment on attitudes towards medication and compliance needs to be a main focus of interventions targeting attitudes towards pharmacological treatment.

References

  • 1 Amering M, Katschnig H. Psychopharmaka im Spannungsfeld zwischen Patienten, Angehörigen und Betreuern. In: Platz T (Ed.) Brennpunkte der Schizophrenie - Gesellschaft-Angehörige-Therapie. Springer-Verlag Wien New York; 1993: 223-231
    Google Scholar
  • 2 Angermeyer M C, Matschinger H. Public attitudes towards psychotropic drugs: have there been any changes in recent years?.  Pharmacopsychiatry. 2004;  37 152-156
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Awad A G. Subjective response to neuroleptics in schizophrenia.  Schizophr Bull. 1993;  19 609-618
    PubMedGoogle Scholar
  • 4 Bäuml J, Pitschel-Walz G, Kissling W. Psychoedukative Gruppen bei schizophrenen Psychosen: Spezifische Auswirkungen eines bifokalen Ansatzes auf Krankheitsbewältigung und Rezidivraten im 4-Jahreszeitraum. Ergebnisse der Münchner PIP-Studie. In: Dittmar V, Klein HE, Schön D, eds Die Behandlung schizophrener Menschen. Integrative Therapiemodelle und ihre Wirksamkeit. S. Roderer Verlag Regensburg; 1997: 169-195
    Google Scholar
  • 5 Bitter I, Chou J C-Y, Ungvari G S, Tang W K, Xiang Z, Iwanami A, Gaszner P. Prescribing for inpatients with schizophrenia: an international multi-center comparative study.  Pharmacopsychiat. 2003;  36 143-149
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Cabeza I G, Amador M S, Lopez C A, Gonzalez de Chavez M. Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors.  Schizophr Res. 2000;  41 349-355
    CrossrefPubMedGoogle Scholar
  • 7 Croghan T W, Tomlin M, Pescosolido B A, Schnittker J, Martin J, Lubelle K eri, Swindle R. American attitudes toward and willingness to use psychiatric medications.  J Nerv Ment Dis. 2003;  191 166-174
    CrossrefPubMedGoogle Scholar
  • 8 Dolder C R, Lacro J P, Dunn L B, Jeste D V. Antipsychotic medication adherence: is there a difference between typical and atypical agents?.  Am J Psychiatry. 2002;  159 103-108
    CrossrefPubMedGoogle Scholar
  • 9 Draine J, Solomon P. Explaining attitudes toward medication compliance among a seriously mentally ill population.  J Nerv Ment Dis. 1994;  82 50-54
    PubMedGoogle Scholar
  • 10 Fenton W S, Blyler C R, Heinssen R K. Determinants of medication compliance in schizophrenia: empirical and clinical findings.  Schizophr Bull. 1997;  23 637-651
    Google Scholar
  • 11 Gervin M, Browne S, Garavan J, Roe M, Larkin C, O'Callaghan E. Dysphoric subjective response to neuroleptics in schizophrenia: relationship to extrapyramidal side effects and symptomatology.  Eur Psychiatry. 1999;  14 405-409
    CrossrefPubMedGoogle Scholar
  • 12 Grohmann R, Engel R R, Geissler K H, Rüther E. Psychotropic drug use in psychiatric inpatients: recent trends and changes over time - data from the AMSP study.  Pharmacopsychiatry. 2004;  37 Suppl 1 S27-38
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Hiller W, Zaudig M, Mombour W. IDCL/ICD 10 International Diagnostic Checklists. IDCL Internationale Diagnosen Checklisten für ICD-10 und DSM-IV. Verlag Huber Bern; 1995
    Google Scholar
  • 14 Hofer A, Kemmler G, Eder U, Honeder M, Hummer M, Fleischhacker W W. Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia.  J Clin Psychiatry. 2002;  63 49-53
    PubMedGoogle Scholar
  • 15 Hogan T P, Awad A G, Eastwood R. A self-report scale predictive of drug compliance in schizophrenia: reliability and discriminative ability.  Psychol Med. 1983;  13 177-183
    PubMedGoogle Scholar
  • 16 Holzinger A, Löffler W, Müller P, Priebe S, Angermeyer M C. Subjective illness theory and antipsychotic medication compliance by patients with schizophrenia.  J Nerv Ment Dis. 2002;  190 597-603
    CrossrefPubMedGoogle Scholar
  • 17 Jaeger J, Bitter I, Czobor P, Volavka J. The measurement of subjective experience in schizophrenia: The Subjective Deficit Syndrome Scale.  Compr Psychiatry. 1990;  31 (3) 216-226
    PubMedGoogle Scholar
  • 18 Jorm A F. Mental health literacy. Public knowledge and beliefs about mental disorders.  Br J Psychiatry. 2000;  177 396-401
    CrossrefPubMedGoogle Scholar
  • 19 Kampman O, Lehtinen K. Compliance in psychoses.  Acta Psychiatr Scand. 1999;  100 167-175
    PubMedGoogle Scholar
  • 20 Kay S R, Fiszbein A, Opler L A. The positive and negative syndrome scale (PANSS) for schizophrenia.  Schizophr Bull. 1987;  13 (2) 261-276
    CrossrefPubMedGoogle Scholar
  • 21 Keith S J, Kane J M. Partial compliance and patient consequences in schizophrenia: our patients can do better.  J Clin Psychiatry 2003;. 64;  11 1308-1315
    PubMedGoogle Scholar
  • 22 Kemp R, Kirov G, Everitt B, Hayward P, David A. Randomised controlled trial of compliance therapy. 18-month follow-up.  Br J Psychiatry. 1998;  172 413-419
    CrossrefPubMedGoogle Scholar
  • 23 Krampen G. FKK, Fragebogen zu Kompetenz- und Kontrollüberzeugungen (Competence and Control Orientations Questionnaire). Hogrefe Göttingen; 1991
    Google Scholar
  • 24 Lambert M, Graf Schimmelmann B, Karow A, Naber D. Subjective well-being and initial dysphoric reaction under antipsychotic drugs - concepts, measurement and clinical relevance.  Pharmacopsychiat. 2003;  36 (suppl 3) S181-S190
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Lauber C, Nordt C, Falcato L, Rossler W. Lay recommendations on how to treat mental disorders.  Soc Psychiatry Psychiatr Epidemiol. 2001;  36 553-556
    CrossrefPubMedGoogle Scholar
  • 26 Linden M, Nather J, Wilms H U. Definition, significance and measurement of illness concepts of patients. The Illness Concept Scale (KK-scale) for schizophrenic patients.  Fortschr Neurol Psychiatr. 1988;  56 35-43
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Löffler W, Kilian R, Toumi M, Angermeyer M C. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment.  Pharmacopsychiat. 2003;  36 105-112
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Lohaus A, Schmitt G M. KKG (Multidimensional Health Locus of Control Scale (MHLC; Wallston, K.A., Wallston, B.S., & DeVellis, R., 1978) - German modified version). Hogrefe Göttingen; 1989
    Google Scholar
  • 29 McCue R E, Waheed R, Urcuyo L. Polypharmacy in patients with schizophrenia.  J Clin Psychiatry. 2003;  64 984-989
    CrossrefPubMedGoogle Scholar
  • 30 Mezzich J E, Ruiperez M A, Perez C, Yoon G, Liu J, Mahmud S. The Spanish version of the quality of life index. presentation and validation.  J Nerv Ment Dis. 2000;  188 (5) 301-5
    CrossrefPubMedGoogle Scholar
  • 31 Noordsy D L, Torrey W C, Mead S, Brunette M, Potenza D, Copeland M E. Recovery-oriented psychopharmacology: redefining the goals of antipsychotic treatment.  J Clin Psychiatry. 2000 ;  61 (suppl 3) 22-29
    PubMedGoogle Scholar
  • 32 O'Donnell C, Donohoe G, Sharkey L, Owens N, Migone M, Harries R, Kinsella A, Larkin C, O'Callaghan E. Compliance therapy: a randomised controlled trial in schizophrenia.  BMJ. 2003;  327 (7419) 834
    CrossrefPubMedGoogle Scholar
  • 33 Procyshyn R M, Thompson B. Patterns of antipsychotic utilization in a tertiary care psychiatric institution.  Pharmacopsychiatry. 2004;  37 12-17
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Rettenbacher M A, Burns T, Kemmler G, Fleischhacker . Schizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medication.  Pharmacopsychiatry. 2004;  37 103-109
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Rossi A, Arduini L, Stratta P, Pallanti S. Subjective experience and subjective response to neuroleptics in schizophrenia.  Compr Psychiatry. 2000;  41 446-449
    CrossrefPubMedGoogle Scholar
  • 36 Ruscher S M, de Wit R, Mazmanian D. Psychiatric patients' attitudes about medication and factors affecting noncompliance.  Psychiatr Serv. 1997;  48 82-85
    PubMedGoogle Scholar
  • 37 Zygmunt A, Olfson M, Boyer C A, Mechanic D. Interventions to improve medication adherence in schizophrenia.  Am J Psychiatry. 2002;  159 1653-1664
    Google Scholar

Ingrid Sibitz, M.D.

Department of Psychiatry

Medical University of Vienna

Währinger Gürtel 18-20

A-1090 Vienna

Phone: 0043/1/40400-3546

Fax: 0043/1/40400-3605

Email: Ingrid.Sibitz@meduniwien.ac.at